---
title: "688166.SH (688166.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688166.SH/news.md"
symbol: "688166.SH"
name: "688166.SH"
parent: "https://longbridge.com/en/quote/688166.SH.md"
datetime: "2026-05-20T05:17:51.647Z"
locales:
  - [en](https://longbridge.com/en/quote/688166.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688166.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688166.SH/news.md)
---

# 688166.SH (688166.SH) — Related News

### ["Flu miracle drug" hard to sell? BrightGene shifts focus to weight loss drugs, aiming for Hong Kong stock market](https://longbridge.com/en/news/286886958.md)
*2026-05-19T09:19:10.000Z*
> BrightGene announced on May 18th that it has re-submitted its H-share issuance application to the Hong Kong Stock Exchan

### [BrightGene: Re-submitted the application for H-share issuance and listing to the Hong Kong Stock Exchange](https://longbridge.com/en/news/286772207.md)
*2026-05-18T12:37:35.000Z*
> BrightGene announced that the company has re-submitted the application for this issuance to the Hong Kong Stock Exchange

### [](https://longbridge.com/en/news/286768380.md)
*2026-05-18T12:08:16.000Z*
> According to Hong Kong Stock Exchange documents: BrightGene (Suzhou) Co., Ltd. has submitted a listing application to th

### [02:08 ETGIP Moves from Supporting Role to Key Variable: BrightGene Bio-Medical's Phase III Results Signal Differentiation in Weight Loss Arena](https://longbridge.com/en/news/286043381.md)
*2026-05-12T06:10:40.000Z*
> BrightGene Bio-Medical's Phase III clinical trial results for BGM0504 show significant weight loss and improvements in v

### [](https://longbridge.com/en/news/286037190.md)
*2026-05-12T05:05:45.000Z*
> Selective movements in A-share innovative drug stocks: TJPC hit the daily limit in the afternoon, Hengrui Pharma rose ov

### [GIP has transitioned from a supporting role to an important variable, and BrightGene may trigger a new round of differentiation in the weight loss sector](https://longbridge.com/en/news/285650546.md)
*2026-05-08T02:07:18.000Z*
> BrightGene's latest disclosure of the Phase III clinical data for BGM0504 has attracted market attention, with an averag

### [Reduction of new drug Phase III clinical success, BrightGene may secure a market entry ticket worth hundreds of billions](https://longbridge.com/en/news/285570486.md)
*2026-05-07T14:10:13.000Z*
> BrightGene announced that its BGM0504 injection has achieved success in Phase III clinical trials, reaching the primary 

### [12:10 ET19.3% Weight Reduction, 16.5 cm Waist Circumference Decrease, SBP/DBP Reductions of 22.9/12.9 mmHg, 70.7 μmol/L Uric Acid Reduction, and 33.6% Triglyceride Reduction: BGM0504 Demonstrates Comprehensive Cardiometabolic Regulation Capabilities](https://longbridge.com/en/news/285409408.md)
*2026-05-06T16:12:20.000Z*
> BrightGene Bio-Medical Technology Co., Ltd. announced positive results from a Phase III trial of its BGM0504 injection,